Cholestatic Pruritus – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Cholestatic pruritus manifests as severe itching without a primary rash, often leading to secondary lesions from scratching. Its pathogenesis is complex and not fully understood, with multiple pruritogens likely involved rather than a single systemic mediator. The development of cholestatic pruritus is multifaceted, intricate, and lacks clear delineation. While some suggest a model wherein a singular systemic pruritogen induces itch, multiple pruritogens probably play a role. A more holistic understanding of cholestatic pruritus would encompass separate influences from bile acids, lysophosphatidic acid (LPA), endogenous opiates, and progesterone derivatives, which are frequently heightened in cases of cholestasis. Patients often regard pruritus as one of the most distressing symptoms of their cholestatic condition, leading to a notable decline in their quality of life. Initial evaluation typically includes tests such as complete blood count (CBC), thyroid function tests, renal function tests, chest X-ray, and markers of cholestasis and liver disease. Cholestyramine serves as the first-line therapy, acting as an anion exchange resin to bind and sequester systemic bile salts, thereby relieving symptoms. Rifampin is considered second-line therapy, aiming to modify the metabolism of specific pruritogens.
Thelansis’s “Cholestatic Pruritus Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Cholestatic Pruritus treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Cholestatic Pruritus across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Cholestatic Pruritus Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment